An analysis of challenges and strategies for integrating HER2-directed therapies into decision-making for NSCLC, with a focus on timely updates, collaborative efforts among stakeholders, and balancing equitable access with cost management.
Video content above is prompted by the following:
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Real-World Data Confirm Ibrutinib's Role in Relapsed CLL
November 26th 2024This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Real-World Data Confirm Ibrutinib's Role in Relapsed CLL
November 26th 2024This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.
Read More
2 Commerce Drive
Cranbury, NJ 08512